Filing Flows › ImmunityBio (IBRX) › Stock forecast & fair value
ImmunityBio (IBRX) stock forecast and price target
ImmunityBio (IBRX) trades at $8.63. 4 analysts' median price target is $14.50 (+68%), from $12.00 to $16.00.
ImmunityBio's latest quarter
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IBRX stock?
The median of 4 analysts' 12-month targets is $14.50, +68% from $8.63; the range is $12.00 to $16.00. The average rating is none.
Does ImmunityBio usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is IBRX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.